Prognostic factors of ovarian cancer;Prognostické faktory ovariálního karcinomu

Ceska Gynekologie

Volumn 71, Issue 3, 2006, Pages 252-259

  Jančárková, Natalie ^a,b   Krkavcova M ^a   Janashia, M ^a   Freitag, P ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Ovarian cancer; Overall survival; Prognostic factors; Tumor characteristics

Indexed keywords

CANCER SURVIVAL; MEDICAL LITERATURE; MEDICAL RESEARCH; OVARY CANCER; PROGNOSIS; REVIEW;

CARCINOMA; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33744799045     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Abd-Elaziz, M., Moriya, T., Akahira, J., et al. Immunolocalization of nuclear transcription factors, DAX-1 and Ad4BP/SF-1, in human common epithelial ovarian tumors: correlations with star and steroidogenic enzymes in epithelial ovarian carcinoma. Int. J. Gynecol. Pathol., 2005, 24, 2, p. 153-163.
2. Abd-Elaziz, M., Moriya, T., Akahira, J., et al. StAR and progesterone producing enzymes (3β-hydroxysteroid dehydrogenase and cholesterol side-chain cleavage cytochromes P450) in human epithelial ovarian carcinoma: Immunohistochemical and real-time PCR studies. Cancer Science, 2005, 96, 4, p. 232-239.
3. Adib, T. R., Henderson, S., Perrett, C., et al. Predicitng biomarkers for ovarian cancer using gene-expression microarrays. Br. J, Cancer, 2004, 90, p. 686-692.
4. Agarwal, R., Kaye, S. B. Prognostic factors in ovarian cancer: how close are we to a complete picture?. Ann. Oncol., 2005, 16, 1, p. 4-6.
5. Aunoble, B., Sanches, R., Didier, E., et al. Major oncogenes and tumor supressor genes involved in epithelial ovarian cancer (rev.). Int. J. Oncol., 2000, 16, 3, p. 567-576.
6. Barbieri, F., Lorenzi, P., Ragni, N., e al. Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology, 2004, 66, 4, p. 310-315.
7. Baron, A. T., Boardman, C. H., Lafky, J. M., et al. Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiology Biomarkers & Prevention. 2005, 13, p. 306-318.
8. Berchuk, A. Biomarkers in the ovary. J. Cell. Biochem., 1995, Suppl. 23, p. 223-226.
9. Bernardini , M., Weberpals, J., Squire, J. A. The use of cytogenetics in understanding ovarian cancer. Biomed. Pharmacother., 2004, 1, p. 17-23.
10. Bosze P. (ed.). Consensus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology. Eur. J. Gynecol. Oncol., 2000, XXI, 6, p. 513-526.
11. Dal Maso, L., Augustin, L. S., Franceschi, S., et al. Association between components of the insulin-like growth factor system and epithelial ovarian cancer risk. Oncology, 2004, 67, 3-4, p. 225-230.
12. Davidson, B., Goldberg, I., Tell, L., et al. The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin. Exp. Metastasis, 2004, 21, 3, p. 191-1999.
13. Denkert, C., Schmitt, W. D., Berger, S., et al. Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int. J. Cancer. 2002, 102, 5, p. 507-513.
14. Eder, A. M., Sui, X., Rosen, D. G., et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc. Natl. Acad. Sci USA, 2005, 102, 35, p. 12519-12524.
15. Farley, J., Smith, L. M., Darcy, K. M., et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: A Gynecologic Oncology Group Study. Cacer Res., 2003, 63, p. 1235-1241.
16. Ferrario , A., Chantrain, C. F., von Thiel, K., et al. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res, 2004, 64, p. 2328-2332.
17. Franke, F. E., Von Georgi, R., Zygmunt, M., et al. Association between fibronectin expression and prognosis in ovarian carcinoma. Anticancer Res., 2003, 23, 5b, p. 4261-4267.
18. Fujimoto, J., Aoki, I., Toyoki, H., e al. Clinical implications of expression of ETS-I related to angiogenesis in metastatic lesions of ovarian cancers. Oncology, 2004, 66, p. 420-428.
19. Geisler, J. P., Geisler, H. E. Tumor markers and molecular biological markers in gynecological malignancies.. Curr. Opin. Obstet. Gynecol.,2001, 13, 1, p. 31-39.
20. nd ed. New York: UICC. Wiley-Liss, 2001, 809 p.
21. Gottwald, L., Danilewicz, M., Suzin, J., et al. AgNORs count correlates better than grading with the effect of chemotherapy in serous ovarian cancer. Pol. J. Pathol., 2003, 54, 4, p. 239-242.
22. Hajduch, M., Jarošová, M., Trojanec, R., et al. Cytogenetické a molekulárně biologické markery v onkologii solidních nádorů a hematologických malignit. Klin. Onkol., 2004, 17, Suppl., s. 51-56.
23. Hata, K., Nakayama, K., Fujiwaki, R., et al. Expression of the angopoietin-1, angopoietin-2, Ti-2 and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol, 2004, 93, 1, p. 215-222.
24. Heimburg, S., Oehler, M. K., Papadopoulos, T., et al. Pro gnostic relevance of the endothelial marker CD 34 in ovarian cancer. Anticancer Res., 1999, 19, 4A, p. 2527-2529.
25. Hogdall, E. V., Johansen, J. S., Kjaer, S. K., et al. Hogh plasma YKL-40 level in patients with ovarian cancer stage III stage is related to shorter survival. Oncol. Res., 2003, 10, 5, p. 1535-1538.
26. Hogdall, E. V., Ryan, A., Kjaer, S., et al. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the. Danish "MALOVA" Ovarian Carcinoma Study. Cancer, 2004, 100, 11, p. 2387-2395.
27. Holschneider, C. H., Berek, J. S. Ovarian cancer: epidemiology, biology and prognostic factors. Semin. Surg. Oncol., 2000, 19, 1, p. 3-10.
28. Holzmayer, T. A., Hilsenbeck, S., Von Hoff, D. D., et al. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J. NCI, 84, 19, p. 1486-1491.
29. Hu, J., Khanna, V., Jones, M. W., Surti, U. Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis. Gynecol. Oncol., 2003, 89, 3, p. 369-375.
30. Ikeda, K., Sakai, K., Yamamoto, R., et al. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1 and p53 in stages II-IV ovarian cancer. J. Gynecol. Cancer, 2003, 13, 6, 776-784.
31. Jančárková, N., Krkavcová, M., Janashia, M., et al. Genetické aspekty maligních epiteliálních nádorů ovaria. Čes. Gynek., 2005, 70, 4, s. 299-306.
32. Jazaeri, A. A., Awtrey, C. S., Gadisetti, V. R., et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin. Cancer Res., 2005, 11, p. 6300-6310.
33. Kaiser, P. C., Korner, M., Kappeler, A., et al. Retinoid receptors in ovarian cancer: expression and prognosis. Ann. Oncol., 2005, 16, 9, p. 1477-1487.
34. Kim, J.-H., Skates, S. J., Uede, T., et al. Ostepontin as a potential diagnostic biomarker for ovarian cancer. JAMA, 2002, 287, p. 1671-1679.
35. Khalifeh, I., Munkarah, A., Lonardo, F., et al. Expression of Cox-2, CD43, Bcl-2 and p53 and survival in patients with primary peritoneal sreous carcinoma and primary ovarian serous carcinoma. Int. J. Gyn. Pathol., 2004, 23, 2, p. 162-169.
36. Kyriakopoulou, L. G., Yousef, G. M., Scorilas, A., et al. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin. Biochem., 2003, 36, 2, p. 135-143.
37. Langdon, S. P., Smyth, J. F. Growth factors and ovarian cancer. Endocrine-Related Cancer, 1998, 5, p. 283-291.
38. Liu, Y., Ganesan, T. S. Tumour supressor genes in sporadic epithelial ovarian cancer. Reproduction, 2002, 123, 3, p. 341-353.
39. Losch, A., Schindl, M., Kohlberger, P., et al. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol. Oncol., 2004, 92, 2, p. 545-552.
40. Matsumoto, K., Bay, B.-H. Significance of the Y-box proteins in human cancers. J. Mol. Genet. Med., 2005, 1, 1, p. 11-17.
41. Matzusaki, H., Kobayashi, H., Yagyu, T. plasma bikunin as a favorable prognostic factor in ovarian cancer. J. Clin. Oncol., 2005, 23, 7, p. 1463-1472.
42. Marx, D., Meden, H., Brune, T., et al. Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anticancer Res., 1997, 17, 1B, p. 775-780.
43. McIntosh, M. Could high plasma bikunin predict a favorable outcome in ovarian cancer? Nature Clin. Prac. Oncol., 2005, 2, p. 502-503.
44. Munkarah, A., Ali-Fehmi, R. COX-2: a protein with an active role in gynecological cancers. Curr. Opin. Obstet. Gynecol., 2005, 17, 1, p. 49-53.
45. Nielsen, J. S., Jakobsen, E., Holund, B., et al. Prognostic significance of p53, Her-2 and EGFR overexpression in borderline and epithelial ovarian cancer. Int. J. Gynecol. Cancer, 2004, 14, 6, p. 1086.
46. Pieretti, M., Hopenhayn-Rich, C., Khatta, N. H., et al. Heterogenity of ovarian cancer: relationship among histological group, stage of disease, tumor markers, patient characteristics and survival. Cancer Invest., 2002, 20, 1, p. 11-23.
47. Rejthar, A., Vojtěšek, B. Obecná patologie nádorového růstu. Praha: Grada Publishing, 2002, 206 s.
48. Sah, S. P., Dawar, R., Kumar, L., et al. Nucleolar organizer regions as a prognostic indicator in epithelial cancers of the ovary. Int. J. Gynecol. Pathol., 2004, 23, 4, p. 347-353.
49. Schaner, M. E., Davidson, B., Sjrede, M., et al. Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol. Cancer, 2005, 4, 26.
50. Scorilas, A., Borgono, C. A., Harbeck, N., et al. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J. Clin. Oncol., 2004, 22, 4, p. 678-685.
51. Sevinc, A., Camci, C., Turk, H. M., et al. How to interprete serum CA 125 levels in patients with serosal involvement: A clinical dilemma. Oncology, 2003, 65, 1, p. 1-6.
52. Shigemasa, K., Gu, L., O'Brien, T., J. e al. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin. Cancer Res., 2003, 9, 5, p. 1756-1763.
53. Simojoki, M., Sanatala, M., Risteli, J., et al. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer, comparison to CA 125. Anticancer Res., 2000, 20, 6C, p. 4655-4660.
54. Simojoki, M., Sanatala, M., Risteli, J., et al. Discrepant expression of carboxy- and aminoterminal propeptides of type I procollagen predicts poor clinical outcome in epithelial ovarian cancer. Gynecol. Oncol., 2003, 88, 3, p. 358-362.
55. Skirnisdottir, I., Sorbe, B., Karlsson, M., et al. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma. Int. J. Oncol., 2001, 19, 6, p. 1295-1302.
56. Skirnisdottor, I., Sorbe, T., Seidal T. The growth receptors HER-2/neu and EGFR, their relationship and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int. J. Gynecol. Cancer, 2001, 11, 2, p. 119-129.
57. Sood, A. K., Fletcher, M. S., Gruman, L. M., et al. The paradoxical expression of maspin in ovarian carcinoma. Clin. Cancer Res., 2002, 8, 9, 2924-2932.
58. Stewart, B. W., Kleihues, P. (eds.) World Cancer Report (WHO). Lyon: IARCPress, 2003, 351 p.
59. Suzuki, M., Kobayashi, H., Tanaka, Y., et al. Bikunin target genes in ovarian cancer cells identified by microarray analysis. J. Biol. Chem., 2003, 278, 17, p. 14640-14646.
60. Špaček, J., Jílek, P., Peter, J., Tesařík, Z. Histopatologické prognostické faktory, sérové markery a vybrané molekulárně biologické faktory u ovariálního karcinomu. Čes. Gynek., 2002, 67, 6, s. 343-349.
61. Terauchi, F., Okamoto, A., Nagashima, T., et al. Clinical significance of p21 (WAF1/CIP1) and p53 expression in seorus cystadenocarcinoma of the ovary. Oncol. Rep., 2005, 14, 2, p. 363-368.
62. Wang, Y., Helland, A., Holm, R., et al. TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br. J. Cancer, 2004, 90, p. 678-685.
63. Warrenfeltz, S., Pavlik, S., Datta, S., et al. Gene expression profiling ovarian tumours correlated with malignant potential. Mol. Cancer, 2004, 3, p. 27.
64. Weichert, W., Denkert, C., Schmidt, M., et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br. J. Cancer, 2004, 90, p. 815-821.
65. Zvárová, J. Základy statistiky pro biomedicínské obory I. Praha: Karolinum, 2002, s. 218.
66. Žaloudík, J., Vyzula, R., Dušek, L. Potřebujeme prediktivní onkologii?. Klin. Onkol., 1999, 12, 3, s. 110-111.